262 related articles for article (PubMed ID: 28245776)
1. Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
Suba Z
Recent Pat Anticancer Drug Discov; 2017; 12(2):136-147. PubMed ID: 28245776
[TBL] [Abstract][Full Text] [Related]
2. The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance.
Suba Z
Drug Des Devel Ther; 2015; 9():4341-53. PubMed ID: 26273195
[TBL] [Abstract][Full Text] [Related]
3. Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
Suba Z
Recent Pat Anticancer Drug Discov; 2018; 13(4):428-444. PubMed ID: 30027855
[TBL] [Abstract][Full Text] [Related]
4. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
6. Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations.
Suba Z
J Oncol; 2020; 2020():5418365. PubMed ID: 32774370
[TBL] [Abstract][Full Text] [Related]
7. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
8. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
[TBL] [Abstract][Full Text] [Related]
9. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Schwarz LJ; Fox EM; Balko JM; Garrett JT; Kuba MG; Estrada MV; González-Angulo AM; Mills GB; Red-Brewer M; Mayer IA; Abramson V; Rizzo M; Kelley MC; Meszoely IM; Arteaga CL
J Clin Invest; 2014 Dec; 124(12):5490-502. PubMed ID: 25401474
[TBL] [Abstract][Full Text] [Related]
10. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
[TBL] [Abstract][Full Text] [Related]
11. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.
Zhang X; Ding L; Kang L; Wang ZY
PLoS One; 2012; 7(1):e30174. PubMed ID: 22276155
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
15. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.
Gomez BP; Riggins RB; Shajahan AN; Klimach U; Wang A; Crawford AC; Zhu Y; Zwart A; Wang M; Clarke R
FASEB J; 2007 Dec; 21(14):4013-27. PubMed ID: 17660348
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
[TBL] [Abstract][Full Text] [Related]
17. William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer.
Katzenellenbogen BS; Montano MM; Ekena K; Herman ME; McInerney EM
Breast Cancer Res Treat; 1997 May; 44(1):23-38. PubMed ID: 9164675
[TBL] [Abstract][Full Text] [Related]
18. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.
Katzenellenbogen BS; Miller MA; Mullick A; Sheen YY
Breast Cancer Res Treat; 1985; 5(3):231-43. PubMed ID: 4027393
[TBL] [Abstract][Full Text] [Related]
19. Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.
Laws MJ; Ziegler Y; Shahoei SH; Dey P; Kim SH; Yasuda M; Park BH; Nettles KW; Katzenellenbogen JA; Nelson ER; Katzenellenbogen BS
Breast Cancer Res Treat; 2020 Jun; 181(2):297-307. PubMed ID: 32277377
[TBL] [Abstract][Full Text] [Related]
20. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Wang C; Bai F; Zhang LH; Scott A; Li E; Pei XH
Breast Cancer Res; 2018 Jul; 20(1):74. PubMed ID: 29996906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]